PE20020407A1 - Derivados de quinazolina como antagonistas del receptor adrenergico alfa-1 - Google Patents

Derivados de quinazolina como antagonistas del receptor adrenergico alfa-1

Info

Publication number
PE20020407A1
PE20020407A1 PE2001000870A PE2001000870A PE20020407A1 PE 20020407 A1 PE20020407 A1 PE 20020407A1 PE 2001000870 A PE2001000870 A PE 2001000870A PE 2001000870 A PE2001000870 A PE 2001000870A PE 20020407 A1 PE20020407 A1 PE 20020407A1
Authority
PE
Peru
Prior art keywords
alkyl
metil
amino
antagonists
alpha
Prior art date
Application number
PE2001000870A
Other languages
English (en)
Spanish (es)
Inventor
Cyrus Kephra Becker
Chris Richard Melville
Juerg Roland Pfister
Xiaoming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020407A1 publication Critical patent/PE20020407A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2001000870A 2000-08-31 2001-08-29 Derivados de quinazolina como antagonistas del receptor adrenergico alfa-1 PE20020407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22950300P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
PE20020407A1 true PE20020407A1 (es) 2002-05-21

Family

ID=22861517

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000870A PE20020407A1 (es) 2000-08-31 2001-08-29 Derivados de quinazolina como antagonistas del receptor adrenergico alfa-1

Country Status (19)

Country Link
US (1) US6559153B2 (enExample)
EP (1) EP1315714B1 (enExample)
JP (1) JP3971299B2 (enExample)
KR (1) KR100602929B1 (enExample)
CN (1) CN1308324C (enExample)
AR (1) AR032475A1 (enExample)
AT (1) ATE309240T1 (enExample)
AU (2) AU9378801A (enExample)
BR (1) BR0113585A (enExample)
CA (1) CA2420177C (enExample)
DE (1) DE60114852T2 (enExample)
ES (1) ES2251512T3 (enExample)
GT (1) GT200100181A (enExample)
MX (1) MXPA03001777A (enExample)
PA (1) PA8527901A1 (enExample)
PE (1) PE20020407A1 (enExample)
UY (1) UY26919A1 (enExample)
WO (1) WO2002018348A2 (enExample)
ZA (1) ZA200301082B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199129B2 (en) 2001-08-10 2007-04-03 Monash University Derivatives of morphine-like opioid compounds
AU2003219199A1 (en) * 2002-04-03 2003-10-13 Orion Corporation Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
ATE440825T1 (de) * 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
BRPI0412808A (pt) * 2003-07-24 2006-09-26 Euro Celtique Sa compostos de piperidina e composições farmacêuticas contendo os mesmos
WO2006021345A2 (en) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b)
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
MX2007013606A (es) * 2005-05-04 2007-12-10 Hoffmann La Roche (3,4-dihidro-quinazolin2-il)-(2-ariloxi-etil)-aminas que tienen una actividad en el receptor 5-ht.
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2066584A2 (en) * 2006-09-19 2009-06-10 3M Innovative Properties Company Templated metal oxide particles and methods of making
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2012131399A1 (en) 2011-04-01 2012-10-04 Astrazeneca Ab Therapeutic treatment
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CN110662541B (zh) * 2017-03-12 2023-02-10 王晓冬 多环胺作为阿片受体调节剂
WO2019088095A1 (ja) * 2017-11-02 2019-05-09 国立大学法人九州大学 鎮痛剤及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011698A1 (en) 1995-09-29 1997-04-03 Merck & Co., Inc. ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof

Also Published As

Publication number Publication date
KR100602929B1 (ko) 2006-07-20
UY26919A1 (es) 2002-02-28
DE60114852T2 (de) 2006-07-27
US20020045614A1 (en) 2002-04-18
JP3971299B2 (ja) 2007-09-05
WO2002018348A3 (en) 2002-07-11
KR20030022421A (ko) 2003-03-15
CA2420177A1 (en) 2002-03-07
AU9378801A (en) 2002-03-13
AU2001293788B2 (en) 2007-10-11
EP1315714A2 (en) 2003-06-04
WO2002018348A2 (en) 2002-03-07
BR0113585A (pt) 2003-07-29
MXPA03001777A (es) 2003-06-04
CA2420177C (en) 2008-07-08
ZA200301082B (en) 2004-05-07
GT200100181A (es) 2002-05-23
ES2251512T3 (es) 2006-05-01
PA8527901A1 (es) 2002-07-30
JP2004507527A (ja) 2004-03-11
CN1308324C (zh) 2007-04-04
US6559153B2 (en) 2003-05-06
EP1315714B1 (en) 2005-11-09
AR032475A1 (es) 2003-11-12
DE60114852D1 (de) 2005-12-15
CN1545510A (zh) 2004-11-10
ATE309240T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
RU2294932C2 (ru) Новые производные индола со сродством к рецептору 5-ht6
PE20020735A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
ES2238583T3 (es) Derivados de benzo(d)azepina como antagonistas del receptor 5-ht6.
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
JP3813629B2 (ja) バソプレッシン・アゴニストとしての縮合アゼピン
PE20010574A1 (es) Derivados de indol como ligandos del receptor 5-ht2
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20020298A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1
CA2272640C (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US9522150B2 (en) Alpha adrenergic receptor modulators
AU2009314221B2 (en) 1-(Arylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzimidazoles as 5-Hydroxytryptamine-6 Ligands
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
PE20011114A1 (es) Decahidro-isoquinolinas
RU2135503C1 (ru) N-замещенные производные 3-азабицикло (3.2.0)гептана или их соли с физиологически совместимыми кислотами
PE20011258A1 (es) Derivados de benzocicloalquilenilamina como antagonistas de receptores muscarinicos
AU2003267063B2 (en) 2,4-substituted indoles and their use as 5-HT6 modulators
JP2004532240A5 (enExample)
NO333165B1 (no) Forbindelse og sammensetning, og anvendelse av samme
PE20040828A1 (es) Benzoxazinonas como modulares de 5-hidroxitriptamina (5-ht)
WO1998023610A1 (en) 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists
US6660751B1 (en) Sulfonamide derivatives as 5-HT7 receptor antagonists
US5908844A (en) N-substituted azabicycloalkane derivatives, their preparation and use
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed